Canada · Delayed Price · Currency is CAD NeuPath Health Statistics
Total Valuation
NeuPath Health has a market cap or net worth of CAD 34.32 million. The enterprise value is 43.31 million.
| Market Cap | 34.32M |
| Enterprise Value | 43.31M |
Important Dates
The last earnings date was Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuPath Health has 56.26 million shares outstanding. The number of shares has increased by 2.40% in one year.
| Current Share Class | 56.26M |
| Shares Outstanding | 56.26M |
| Shares Change (YoY) | +2.40% |
| Shares Change (QoQ) | -3.51% |
| Owned by Insiders (%) | 3.01% |
| Owned by Institutions (%) | 10.97% |
| Float | 49.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.63 |
| PS Ratio | 0.39 |
| PB Ratio | 1.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.45 |
| P/OCF Ratio | 8.57 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.01, with an EV/FCF ratio of 13.19.
| EV / Earnings | -60.41 |
| EV / Sales | 0.50 |
| EV / EBITDA | 10.01 |
| EV / EBIT | 21.27 |
| EV / FCF | 13.19 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.09 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 3.04 |
| Debt / FCF | 4.00 |
| Interest Coverage | 2.27 |
Financial Efficiency
Return on equity (ROE) is -1.95% and return on invested capital (ROIC) is 6.82%.
| Return on Equity (ROE) | -1.95% |
| Return on Assets (ROA) | 2.95% |
| Return on Invested Capital (ROIC) | 6.82% |
| Return on Capital Employed (ROCE) | 6.30% |
| Weighted Average Cost of Capital (WACC) | 8.58% |
| Revenue Per Employee | 573,638 |
| Profits Per Employee | -4,717 |
| Employee Count | 152 |
| Asset Turnover | 2.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NeuPath Health has paid 356,000 in taxes.
| Income Tax | 356,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +258.82% in the last 52 weeks. The beta is 1.01, so NeuPath Health's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +258.82% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.40 |
| Relative Strength Index (RSI) | 65.81 |
| Average Volume (20 Days) | 113,840 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeuPath Health had revenue of CAD 87.19 million and -717,000 in losses. Loss per share was -0.01.
| Revenue | 87.19M |
| Gross Profit | 16.59M |
| Operating Income | 2.04M |
| Pretax Income | -57,000 |
| Net Income | -717,000 |
| EBITDA | 3.04M |
| EBIT | 2.04M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 4.47 million in cash and 13.14 million in debt, with a net cash position of -8.67 million or -0.15 per share.
| Cash & Cash Equivalents | 4.47M |
| Total Debt | 13.14M |
| Net Cash | -8.67M |
| Net Cash Per Share | -0.15 |
| Equity (Book Value) | 20.95M |
| Book Value Per Share | 0.37 |
| Working Capital | 1.13M |
Cash Flow
In the last 12 months, operating cash flow was 4.00 million and capital expenditures -718,000, giving a free cash flow of 3.29 million.
| Operating Cash Flow | 4.00M |
| Capital Expenditures | -718,000 |
| Depreciation & Amortization | 1.01M |
| Net Borrowing | -1.39M |
| Free Cash Flow | 3.29M |
| FCF Per Share | 0.06 |
Margins
Gross margin is 19.03%, with operating and profit margins of 2.34% and -0.82%.
| Gross Margin | 19.03% |
| Operating Margin | 2.34% |
| Pretax Margin | -0.07% |
| Profit Margin | -0.82% |
| EBITDA Margin | 3.49% |
| EBIT Margin | 2.34% |
| FCF Margin | 3.77% |
Dividends & Yields
NeuPath Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.40% |
| Shareholder Yield | -2.40% |
| Earnings Yield | -2.09% |
| FCF Yield | 9.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuPath Health has an Altman Z-Score of 1.65 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 5 |